Focus on Rheumatoid Arthritis


The Rheumatology Network rheumatoid arthritis clinical focus page provides information on the latest rheumatoid arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for rheumatoid arthritis drugs.

Tofacitinib Does Not Increase Risk of Venous Thromboembolism in Patients With RA

March 31, 2021

Recently, a link between venous thromboembolism (VTE) and Janus Kinase (JAK) inhibitors has emerged, causing the FDA to recommend a black box label for tofacitinib in 2019. New research, however, suggests that tofacitinib had similarly infrequent cases of VTE (

CreakyJoints Saves and Renames John Whelton Arthur Virshup CreakyJoints South Florida Arthritis Clinic

March 26, 2021

This week, Rheumatology Network interviewed Michael C. Schweitz, MD, to discuss the recent press release published by CreakyJoints that announced their partnership with the John Whelton Arthur Virshup CreakyJoints South Florida Arthritis Clinic.

Jack March: Exercises for Patients with Rheumatoid Arthritis

March 19, 2021

In this video, Jack March, a physiotherapist specializing in rheumatology, demonstrates exercises for rheumatoid arthritis (RA) relief. He discusses providing exercises for patients, how to prescribe them, reasons to get patients to exercise, and the many benefits that come from engaging in a workout routine.

Arthur Kavanaugh, MD: Rheumatology Winter Clinical Symposium

February 10, 2021

This week we sat down for an interview with Arthur Kavanaugh, MD, to discuss his presentations for the Rheumatology Winter Clinical Symposium. He is currently the chairman for the 2021 conference. Kavanaugh is Professor of Medicine and Director of the Center for Innovative Therapy at UC San Diego. He will be presenting his findings on Rheumatology 2020: A Year in Review for rheumatoid arthritis, spondylarthritis, and psoriatic arthritis. We discuss what sets RWCS apart from other conferences and the exciting content that participants can expect.

Tocilizumab Does Not Improve Outcomes for Patients With Severe COVID-19

February 03, 2021

Tocilizumab is an interleukin 6 (an inflammatory cytokine) inhibitor approved for treating a variety of rheumatic diseases, including rheumatoid arthritis. As studies have shown that an increased level of interleukin 6 directly correlates to poor COVID-19 outcomes, investigators speculated that blocking this activity could be a helpful tool in treating the virus and lessening its severity.

Latino Patients With Rheumatic Diseases are at Higher Risk of Contracting COVID-19

February 01, 2021

The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by COVID-19. Of the patients observed, 32 (18%) developed COVID-19 during the study period, meaning incidence rates were 5- to 11-fold higher than the general population (1,540 to 3,431/100,000).